Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡Richard K. Sterling, Mark Nelson, Mendes Cassia Correa et al.|Hepatology|2006Cited by 4.8k
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean‐Michel Molina, Steven L. Chuck, Anthony LaMarca et al.|The Lancet Infectious Diseases|2011Cited by 172